NEO 212

Drug Profile

NEO 212

Alternative Names: NEO-212

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEONC Technologies
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain metastases; Glioma

Most Recent Events

  • 29 Jul 2016 Preclinical trials in Brain metastases in USA (unspecified route) prior to July 2016
  • 29 Jul 2016 Preclinical trials in Glioma in USA (unspecified route) prior to July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top